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IPD01:
METFORMIN IMPROVE UPPER TRACT UROTHELIAL CARCINOMA
SURVIVAL IN TAIWANESE PATIENTS WITH TYPE 2 DIABETES
Hsiang-Ying Lee 1,2, Ching-Chia Li 1,2, Hsin-Chih Yeh 1,2, Hung-Lung
Ke 1, Chun-Nung Huang 1, Wen-Jeng Wu1,2. 1Department of Urology,
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 2Department of
Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan
Purpose: The oral diabetes medicine metformin might have chemo-
preventive effects against cancer which was discussed before. However, no
clinical study exists for analyzing the effect of metformin in upper tract
urothelial carcinoma survival condition in type 2 diabetes patients which
presents an unusual feature in Taiwan. Therefore, we want to realize if
metformin can improve survival rate in upper tract urothelial carcinoma
patients through a population-based analysis.
Materials and Methods: The reimbursement databases of all Taiwanese
patients with a newly diagnosis of upper tract urothelial carcinoma be-
tween 2003 and 2011 (n ¼ 4418) were retrieved from the National Health
Insurance. Then we just extract type 2 diabetes mellitus patients with
more than two prescriptions diabetes mellitus drugs and delete only 1
prescription of metformin in prior 6 months (n ¼ 826). We calculate
hazard ratios by Cox regression for ever-users and never-users with SAS
statistical method.
Results: Among 826 enrolled patients, there are 358 patients never using
metformin and 468 ever take more than 2 prescription of metformin. 314
patients are male and 512 are female. The median survival time is 4.25
years for never using metformin and 6.97 years for ever-users and the
difference is signiﬁcant statistically. (P ¼ 0.0005) We also assess subgroup
of patients who received standard operation of nephroureterectomy and it
also revealed metformin have better survival rate.
Conclusion: This study suggests that metformin use is associated with
improving survival rate of upper tract urothelial carcinoma in patients
with T2DM.
IPD02:
LONG-TERM RESULT OF TOTAL URETERECTOMYWITH ILEAL-URETERAL
SUBSTITUTION IN THE TREATMENT OF URETERAL CANCER, A SINGLE-
CENTER EXPERIENCE
Yin-Chien Ou, Wen-Horng Yang. Department of Urology, National Cheng
Kung University Hospital, Tainan, Taiwan
Purpose: In the treatment of ureteral urothelial carcinoma, renal-sparing
procedures are of great importance for some well-selected patients.
However, these procedures may carry risks of under-staging and may not
be feasible in multifocal tumor. We performed total ureterectomy in order
to achieve maximal resection of the pathological ureter, and repaired the
ureteral defect with ileal-ureteral substitution.
Materials and Methods:We retrospectively reviewed the medical records
of all patients who underwent total ureterectomy with ileal-ureteral
substitution for ureteral urothelial carcinoma at our center from January
1988 through December 2015. Patient demographics, baseline renal
function, disease etiology, surgical procedures, pathology reports,perioperative and long-term complications, long-term renal function, and
the oncological outcome were recorded for analysis.
Results: A total of eight patients received total ureterectomy with ileal
ureteral substitution with a mean follow up period of 81.8 months. In-
dications included solitary kidney, chronic kidney disease, and bilateral
disease. The common perioperative complications were anastomotic urine
leakage and temporary hemodialysis, and the long-term complication was
mainly urinary tract infection. Preservation for renal functional was good,
with only one deteriorated patient that need life-long hemodialysis. Only
one patient (12.5%) experienced upper tract recurrence, and three patients
(37.5%) had bladder recurrence during follow up. The 5-year recurrence
free survival and cancer speciﬁc survival rate were 50% and 75%,
respectively.
Conclusion: Total ureterectomywith ileal ureteral substitution is a feasible
choice to treat ureteral UC when renal-sparing procedure is indicated. It
provides good long-term oncological outcome over upper tract, and also
preserves the renal function.
IPD03:
ASSOCIATION OF PREOPERATIVE PROTEINURIA WITH RENAL
FUNCTIONAL OUTCOMES AFTER OPEN PARTIAL NEPHRECTOMY IN
PATIENTS WITH AN ANATOMICALLY OR FUNCTIONALLY SOLITARY
KIDNEY
Hidekazu Tachibana, Toshio Takagi, Junpei Iizuka, Tsunenori Kondo, Hideki
Ishida, Kazunari Tanabe. Tokyo Women's Medical University, Department of
Urology, Japan
Purpose: Nephron-sparing surgery is required for patients with an
anatomically or functionally solitary kidney, for postoperative renal
function optimization. Open partial nephrectomy in the solitary kidney
is associated with reliable, long-term renal function, preventing pro-
gression to dialysis. Therefore, we aimed to identify the preoperative
factors associated with renal function decline after open partial
nephrectomy.
Materials and Methods: Patients who underwent open partial nephrec-
tomy for a renal tumor at our institution between 1986 and 2014,
excluding those who underwent ex vivo partial nephrectomy, were
retrospectively analyzed. Multivariate linear regression analysis was used
to test associations of a postoperative decrease in the estimated glomer-
ular ﬁltration rate (eGFR) with perioperative conditions such as the pre-
operative eGFR, preoperative proteinuria, tumor size, and intraoperative
renal ischemia time. Survival rates were analyzed using the Kaplan-Meier
method and log-rank statistics.
Results: In total, 83 patients were included in this study; 5 were excluded.
The median follow-up period for the remaining 78 patients was 34
months. The mean preoperative eGFR, tumor diameter, operative time,
renal ischemic time, and estimated blood loss were 51±14ml/min/1.73m2,
34±22 mm, 243±62 minutes, 41±22 minutes, and 355±333 ml, respec-
tively. In 18 patients (23%), the postoperative eGFR was <30 ml/min/
1.73 m2 12 months after surgery. Only 1 patient needed chronic hemodi-
alysis 12 months after surgery. On multivariate analysis, preoperative
proteinuria (odds ratio [OR] 8.7, 95% conﬁdence interval [CI] 1.6e58.8,
P¼0.01) and eGFR (OR 0.83, 95% CI 0.74e0.91, P¼0.001) were signiﬁcant
predictors of a decrease in eGFR to <30 ml/min/1.73 m2 after surgery. The
probability of freedom from eGFR <30 ml/min/1.73 m2 after 24 months
